Figure 1From: Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer Progression-Free Survival. Median progression free survival for patients in all cohorts was 2.7 months (95% CI, 1.6 to 9.1).Back to article page
